Table 3.
Ongoing trials on the efficacy of NAT for resectable or borderline resectable PC.
| Trial Number | Trial Name | Resectability | Intervention | Comparator | Primary Outcome |
|---|---|---|---|---|---|
| NCT04340141 [48] | Alliance A021806 | R-PC | Perioperative mFOLFIRINOX | Adjuvant mFOLFIRINOX | OS |
| NCT02959879 [40] | PANACE01-PROGIGE 48 | R-PC | Preoperative FOLFOX or mFOLFIRINOX | Upfront surgery | OS |
| NCT04927780 [41] | PREOPANC-3 | R-PC | Perioperative mFOLFIRINOX (8 weeks and 4 weeks) | Adjuvant mFOLFIRINOX (12 weeks) | OS |
| NCT06172036 [43] | CAPT-02 | R-PC | NALIRIFOX with or without adelizumab | Upfront surgery | EFS rate |
| NCT05529940 [45] | NeoFOL-R | R-PC | Perioperative mFOLFIRINOX (6 weeks and 6 weeks) | Adjuvant mFOLFIRINOX (12 weeks) | 2-year survival rate |
| NCT03750669 [46] | CISPD-1 | R-PC | Sequential GEM + nabPTX and mFOLFIRINOX | Upfront surgery | DFS |
| NCT03727880 [47] | - | R-PC | Neoadjuvant pembrolizumab + defactinib | Pembrolizumab | Pathological response rate |
| UMIN000021484 [49] | PDAC-GS/GA-rP2, CSGO-HBP-015 | R-PC/BR-PC | GEM + S-1 | GEM + nab-PTX | PFS |
| NL7094 [50] | PREOPANC-2 | R-PC/BR-PC | Neoadjuvant FOLFIRINOX (8 cycles) without adjuvant treatment | GEM (3 cycles) with RT during the second cycle + adjuvant GEM | OS |
| NCT02676349 [44] | PANDAS-PRODIGE 44 | BR-PC | Neoadjuvant mFOLFIRINOX + CRT (50.4 Gy) | Neoadjuvant mFOLFIRINOX | R0 resection rate |
| NCT04617821 [42] | - | BR-PC | GEM + nabPTX | mFOLFIRINOX | OS |
| NCT03777462 [51] | BRPCNCC-1 | BR-PC | Neoadjuvant GEM + nab-PTX with SBRT, neoadjuvant S-1 + nab-PTX with SBRT | GEM + nab-PTX | OS |
R-PC, resectable pancreatic cancer; BR-PC, borderline resectable pancreatic cancer; SBRT, stereotactic radiotherapy; GEM, gemcitabine; nab-PTX, nab-paclitaxel; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; EFS, event-free survival; R0 resection, complete resection; RT, radiotherapy.